A Dynamically Regulated Designed IL-2 for Tumor-localized Signaling
Preprint
Abstract
Cytokines mediate cell-cell communication to coordinate immune responses and hold clinical promise as immunotherapies 1–3 . While natural cytokines are exquisitely regulated by immune cells, engineered cytokines have not yet matched this sophisticated regulation, limiting clinical efficacy and safety 4,5 . IL-2 is an important cytokine involved in antitumor response, but its production is disrupted in the immune-suppressive tumor microenvironment. Here we designed a regulated IL-2 module, OUTSMART designed IL-2 (dIL-2), that functions robustly in solid tumors and reduces systemic activity that could trigger toxicity: we computationally redesigned IL-2 to have a novel topology that increases stability, preserves native IL-2Rβγ interfaces, ablates IL-2Rα binding, and delivers IL-2 signaling to CD8α+ immune-effector cells. This designed cytokine is genetically regulated by a T cell activation-responsive promoter, allowing dynamic production from chimeric antigen receptor (CAR) T cells. Like wild type IL-2, OUTSMART dIL-2 drives T cell proliferation and enhances effector function. Unlike wild type IL-2, it preferentially stimulates CD8+ T cells and Natural Killer (NK) cells, avoids T regulatory cells, and stimulates CAR-T proliferation while preserving stemness, achieving durable tumor elimination in two solid tumor animal models. These design principles can be applied to create other dynamically-regulated cytokine systems that address mechanisms of complex disease.Keywords
This publication has 41 references indexed in Scilit:
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organismNature Communications, 2021
- Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical ProgressAdvanced Therapeutics, 2021
- Engineering CAR-T Cells for Next-Generation Cancer TherapyCancer Cell, 2020
- Cytokines in clinical cancer immunotherapyBritish Journal of Cancer, 2018
- Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15RαImmunogenetics, 2013
- A novel high‐affinity human monoclonal antibody to mesothelinInternational Journal of Cancer, 2011
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Both integrated and differential regulation of components of the IL-2/IL-2 receptor systemCytokine & Growth Factor Reviews, 2006
- Dissecting α-helices: Position-specific analysis of α-helices in globular proteinsProteins: Structure, Function, and Bioinformatics, 1998
- N‐ and C‐capping preferences for all 20 amino acids in α‐helical peptidesProtein Science, 1995